- Home
- HCTI vs BLRX Comparison
HCTI vs BLRX Comparison
Compare HCTI & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCTI | BLRX |
|---|---|---|
| Founded | 2020 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 12.0M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | HCTI | BLRX |
|---|---|---|
| Price | $0.75 | $2.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 2.3M | 17.3K |
| Earning Date | 04-16-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,891,000.00 | N/A |
| Revenue This Year | $79.33 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.77 | N/A |
| 52 Week Low | $0.14 | $2.15 |
| 52 Week High | $9.97 | $4.56 |
Technical Indicators
Market Signals| Indicator | HCTI | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.04 | 42.35 |
| Support Level | $0.14 | $2.18 |
| Resistance Level | $2.64 | $3.02 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 8.77 | 7.02 |
Price Performance
Historical ComparisonAbout HCTI Healthcare Triangle Inc.
Healthcare Triangle Inc is a healthcare information technology company focused on advancing industry-transforming solutions in the sectors of cloud services, data science, and professional and managed services for the healthcare and life sciences industry. The company reinforces healthcare progress through technology and extensive industry know-how. HTI supports healthcare providers and payors, hospitals, and Pharma Life Sciences organizations in their efforts to improve health outcomes by enabling the adoption of new technologies, data enlightenment, business agility, and accelerated response to immediate business needs and competitive threats. It provides services under three operating segments: Software Services, Managed Services, and Support and Corporate & others.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.